Curlygirl,
The one with the temporary implants is called "high dose rate (HDR) brachytherapy." The one where they leave the seeds inside permanently is called "low dose rate (LDR) brachytherapy (or "seeds")." They are both excellent choices when combined with external beam radiation and hormone therapy.
Because survival rates are so long after treatment of even high risk prostate cancer, they usually look at a different measure of how successful a radiation treatment was. They look to see whether PSA increased significantly (more than 2 points) after going down first. That's called "biochemical" progression-free survival, recurrence-free survival, relapse-free survival, freedom from failure, disease-free survival or no evidence of disease (depending on the study).
As you can see in the top part of the following article about
HDR therapy, the HDR brachy "boost" led to 5-year biochemical relapse-free survival ranging from 67% to 97% with acceptably low rates of long-term toxicity. (HDR brachy monotherapy and SBRT monotherapy are experimental therapies for high risk cases):
HDRBT in treatment of high-risk prostate cancerThe LDR brachy boost was compared to external beam only therapy in a randomized comparison last year. The 7-year progression-free survival was 83% in that study, so very similar to the HDR brachy boost. Long term urinary toxicity was somewhat higher than the HDR boost therapy, but the two weren't compared directly.
EBRT + LDRBT boost provides superior cancer control compared to EBRT aloneWhen these studies speak of "late term grade 3 urinary toxicity" for these kinds of treatments, they are mostly referring to urethral strictures (closing up of the urethra from the swelling and scar tissue) that required surgical intervention (like a stent or TURP). That occurred in 1%-7% of the men in the HDR boost studies and up to 19% of the men in the LDR boost study. The opposite problem, urinary incontinence, is a rare side effect with primary radiation therapy of any kind.
Acute side effects like urinary frequency/retention, urgency, and burning are common within the first 3 months after these treatments, but they usually pass quickly, and medications can help make it more comfortable in the interim.
- Allen